My theory is also that Cytodyn might be leaning to

Quote:

---

My theory is also that Cytodyn might be leaning towards putting out more updates on the cancer trials because they know hey are not the ones pushing these indications through FDA approval, they are looking to license these off ASAP

---

Licensing for development and commercialization overseas prior to Phase 2 completion would most likely result in a much lower % of sales for us. That should be done only for smaller markets and only if necessary.

In the U.S., unless BP is willing to give us a similar deal as the one outlined for HIV (or better) we should hold it until FDA approval.

With Nader looking out for shareholder value I'm sure he'll follow that path,